Skip to main content
Fig. 1 | Clinical Sarcoma Research

Fig. 1

From: A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas

Fig. 1

a Event-Free Survival (EFS) and Progression-free Survival (PFS) of the 15 patients treated at the RP2D. A Kaplan–Meier curve indicating the time from beginning of treatment to withdrawal from study (EFS) or beginning of treatment to first objective evidence of disease progression by RECIST 1.1 criteria (PFS). b EFS and PFS of the 18 patients treated at the RP2D and the dose level above. A Kaplan–Meier curve indicating the time from beginning of treatment to withdrawal from study (EFS) or beginning of treatment to first objective evidence of disease progression by RECIST (PFS). c A waterfall plot of the best responses for the 15 patients treated at R2PD

Back to article page

Clinical Sarcoma Research

ISSN: 2045-3329